foxo4 dri senolytic peptide research The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI FOXO4-DRI: The Senolytic Peptide That

Beyond good and evil: a putative continuum-sorting hypothesis for the functional role of proBDNF/BDNF-propeptide/mBDNF in antidepressant treatment.Neurosci Biobehav Rev.2018;90:7083

Dihexa works by binding to the HGF receptor c-Met on hippocampal neurons, activating intracellular signaling pathways that increase synaptogenesis, dendritic spine density, and NMDA receptor expression

While cagrilintide has not yet been approved for therapeutic use, its mechanisms of action have inspired further exploration in research settings, particularly in preclinical and early-phase clinical studies focused on gastrointestinal and metabolic endpoints

This leads to enhanced cell migration and survival at injury sites